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The periods of embryonic, foetal and infant development
are remarkably susceptible to environmental hazards. Toxic
exposures to chemical pollutants during these windows of
increased susceptibility can cause disease and disability in
infants, children and across the entire span of human life.
Among the effects of toxic exposures recognized in the past
have been spontaneous abortion, congenital malformations,
lowered birthweight and other adverse effects. These outcomes
may be readily apparent. However, even subtle changes caused
by chemical exposures during early development may lead
to important functional deficits and increased risks of
disease later in life. The timing of exposure during early life
has therefore become a crucial factor to be considered in
toxicological assessments.
During 20–24 May 2007, researchers in the fields of environ-
mental health, environmental chemistry, developmental
biology, toxicology, epidemiology, nutrition and paediatrics
gathered at the International Conference on Fetal Pro-
gramming and Developmental Toxicity, in Tórshavn, Faroe
Islands. The conference goal was to highlight new insights
into the effects of prenatal and early postnatal exposure to
chemical agents, and their sustained effects on the individual
throughout the lifespan. The conference brought together
researchers to focus on human data and the translation
of laboratory results to elucidate the environmental risks to
human health.
 
Research State of the Art
 
The developing embryo and foetus are extraordinarily sus-
ceptible to perturbation of the intrauterine environment.
Chemical exposures during prenatal and early postnatal life
can bring about important effects on gene expression, which
may predispose to disease during adolescence and adult life.
Some environmental chemicals can alter gene expression by
DNA methylation and chromatin remodelling. These epigenetic
changes can cause lasting functional changes in specific
organs and tissues and increased susceptibility to disease
that may even affect successive generations.
New research on rodent models shows that developmental
exposures to environmental chemicals, such as hormonally
active substances (endocrine disruptors), may increase the
incidence of reproductive abnormalities, metabolic disorders
such as diabetes, and cancer, presumably through epigenetic
mechanisms that do not involve changes to DNA sequences
but which may, nevertheless, be heritable.
Prenatal exposure to diethylstilboestrol, an oestrogenic
drug no longer used during pregnancy, has been shown to
cause an increased risk of vaginal, uterine and breast cancer
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in human beings and animal models. In animal models, low-
level developmental exposure to a plastics ingredient, bisphenol
A, may increase the susceptibility to breast or prostate cancer,
and prenatal exposure to vinclozoline, a common fungicide,
may also promote later development of cancer. These sub-
stances are only weak carcinogens, if  at all, in the adult
organism but are nonetheless hazardous to the growing foetus.
In addition, when exposure to a carcinogenic substance occurs
during early development, the expected lifespan will exceed
the normal latency period for development of the disease.
The human reproductive system is highly vulnerable to
changes in the intrauterine hormonal environment. In
men, there is an increase in the occurrence of  testicular
cancer, poor semen quality and cryptorchidism, jointly termed
the testicular dysgenesis syndrome. In animals, a similar
combination of outcomes is replicated by developmental
exposure to certain phthalate esters. However, links between
environmental chemicals and the testicular dysgenesis syn-
drome in human beings are still unclear, although suggestive
associations have been found with maternal smoking, fertility
treatment of the mother, phthalate exposure and occupational
exposure to pesticides with suspected oestrogenic and anti-
androgenic activity. Perinatal exposure to endocrine-disrupting
chemicals, such as polychlorinated or polybrominated
biphenyls or dichlorodiphenyltrichloroethane compounds,
may affect puberty development and sexual maturation at
adolescence. Many other environmental chemicals can cause
such effects in animal models. Expression of some of these
effects may be promoted by predisposing genetic traits.
The brain is particularly sensitive to toxic exposures during
development, which involves a complex series of steps that
must be completed in the right sequence and at the right
time. Slight decrements in brain function may have serious
implications for future social functioning and economic
activities, even in the absence of mental retardation or obvious
disease. Each neurotoxic contaminant may perhaps cause only
a negligible effect, but the combination of several toxic
chemicals, along with other adverse factors, such as poor
nutrition, may trigger substantial decrements in brain function.
The immune system also undergoes crucial developmental
maturation both before and after birth. New evidence suggests
that a number of persistent and non-persistent environmental
pollutants may alter the development of the immune system.
Studies in a variety of species of experimental animals indi-
cate polychlorinated biphenyls to be highly immunotoxic.
While exposures of human adults show little indication of
such effects, early life exposures appear capable of inducing
similar aberrations in children as seen in other species. Asthma,
allergic sensitization or greater susceptibility to infections
may be linked to prenatal or early postnatal chemical expo-
sures. In addition, because of multiple interactions between
the immune and nervous systems, abnormal maturation of
immune responsiveness may also be implicated in some neuro-
developmental disorders.
While the research on developmental toxic effects has, to
date, emphasized maternal exposures and the infant environ-
ment, the possibility exists that paternal exposures may also
affect the child’s development. Experimental studies suggest
that ionizing radiation, smoking and certain environmental
chemicals may be of importance, and that some exposures
may affect the health and development of children, as well




Three aspects of children’s health are important in conjunc-
tion with developmental toxicity risks. First, the mother’s
chemical body burden will be shared with her foetus or
neonate, and the child may, in some instances, be exposed to
larger doses relative to the body weight. Second, susceptibility
to a wide range of adverse effects is increased during develop-
ment, from preconception through adolescence, depending
on the organ system. Third, developmental exposures to
environmental chemicals can lead to life-long functional
deficits and disease.
Research into the environmental influence on develop-
mental programming of health and disease has, therefore,
led to a new paradigm of toxicologic understanding. The old
paradigm, developed over four centuries ago by Paracelsus,
was that ‘the dose makes the poison’. However, for exposures
sustained during early development, another critical, but
largely ignored, issue is that ‘the timing makes the poison’.
This extended paradigm deserves wide attention to protect
the foetus and child against preventable hazards.
These insights derive in part from numerous animal studies
indicating that events during the foetal and early postnatal
period may be responsible for reproductive, immunological,
neurobehavioural, cardiovascular and endocrine dysfunctions
and diseases, including certain cancers and obesity. Some of
these adverse effects have been linked to environmental
chemicals at realistic human exposure levels (i.e. levels similar
to those occurring from environmental sources).
Among the mechanisms involved, particular concern is
raised about changes in gene expression due to altered
epigenetic marking, which not only may lead to increased
susceptibility to diseases later in life, but may, in some cases,
also affect subsequent generations.
Most chronic disease processes are characterized by multi-
causality and complexity. Understanding such processes
requires a broad systems approach that focuses on integra-




Studies on the aetiology of human disease need to incorporate
early development and characterize appropriately the factors
that determine organ functions and subsequent disease risks.
Such associations can best be examined in long-term pro-
spective studies, and existing and planned pregnancy or
birth cohorts should be utilized for this purpose.
The aetiology of human disease can be better understood
through cross-disciplinary approaches, translation of animal
data, better exposure biomarkers and understanding indi-
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stimulated among the scientific disciplines involved and
between scientists and policy-makers.
Environmental chemical exposure assessment should
emphasize the time period of early development. Exposure
data already routinely collected should be applied, when
feasible, in epidemiological studies. In addition, cord blood,
cord tissue, human milk and other biological samples should
be collected for assessment of exposure biomarkers and for
determination of gene expression changes.
Because human beings are exposed to numerous chemicals
during development and throughout life, mixed exposures
need to be considered in a life-course approach to disease.
Other factors, such as nutrition, other lifestyle factors and
societal environment, need to be considered for additive or
interactive effects. This research should also capitalize on the
ability of genetic variation and gene–environment interaction
to explore the causal nature of environmental exposures with
respect to health outcomes.
Risk assessment of environmental chemicals needs to take
into account the susceptibility of early development and the
long-term implications of adverse programming in a variety
of organ systems. Although test protocols exist to assess
reproductive toxicity, neurodevelopmental toxicity and immune
toxicity, such tests are not routinely used, and the potential
for such effects is, therefore, not necessarily considered in
decisions on safety levels of environmental exposures.
The accumulated research evidence suggests that prevention
efforts against toxic exposures to environmental chemicals
should focus on protecting the embryo, foetus and small
child as highly vulnerable populations. Given the ubiquitous
exposure to many environmental chemicals, there needs to
be renewed efforts to prevent harm. Healthier solutions
should be researched and proposed in future work. Preven-
tion should not await definitive evidence of causality when
delays in decision-making would lead to the propagation
of toxic exposures and their long-term, harmful conse-
quences. Current procedures, therefore, need to be revised to
address the need to protect the most vulnerable life stages
through greater use of precautionary approaches to exposure
reduction.
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